Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A new scfv-based recombinant immunotoxin against EPHA2-overexpressing breast cancer cells; High in vitro anti-cancer potency.

European journal of pharmacology - 5 Mar 2020

Rezaie Ehsan, Amani Jafar, Bidmeshki Pour Ali, Mahmoodzadeh Hosseini Hamideh

Abstract excerpt

Immunotoxin therapy is one of the immunotherapy strategies providing a new, effective and high potency treatment against various cancers. Breast cancer is the most common cancer among women in many countries. The EPH receptors are a large part of tyrosine kinase receptors family and play an effective role in tumor development and angiogenesis. Among EPH receptors, EPHA2 is more commonly well-known and widely...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Apoptosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytoplasm

Share to Immunotherapy

Share to Immunotoxins

Share to Neoplasm Metastasis

Share to Recombinant Proteins

Share to Single-Chain Antibodies

Source

Identifiers

PMID: 31926992
DOI: 10.1016/j.ejphar.2020.172912

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A new scfv-based recombinant immunotoxin against EPHA2-overexpressing breast cancer cells; High in vitro anti-cancer potency.PMID 31926992Read ↗

Design and Evaluation of Eb4Mab-7-mG2a: A Dual-Action Anti-EphB4 Monoclonal Antibody for Targeted Breast Cancer TherapySemantic proximity Read ↗

Bioactivity of Recombinant Humanized Monoclonal Antibody Against HER2 and Its Mechanism of Action on Ovarian CancerSemantic proximity Read ↗

Identification and characterization of tumor antigens by using antibody phage display and intrabody strategies.Semantic proximity Read ↗

EphB2-Targeting Monoclonal Antibodies Exerted Antitumor Activities in Triple-Negative Breast Cancer and Lung Mesothelioma Xenograft ModelsSemantic proximity Read ↗

Development of a MET-targeted single-chain antibody fragment as an anti-oncogene targeted therapy for breast cancerSemantic proximity Read ↗

T cells expressing a HER2-specific chimeric antigen receptor as treatment for breast cancerSemantic proximity Read ↗

Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: targeting with a single chain antibody variable domain isolated by phage display.Semantic proximity Read ↗

Annexin A2 and its downstream IL-6 and HB-EGF as secretory biomarkers in the differential diagnosis of Her-2 negative breast cancer.Semantic proximity Read ↗

Engineered Bifunctional Proteins for Targeted Cancer Therapy: Prospects and ChallengesSemantic proximity Read ↗

Exosomes containing miRNAs targeting HER2 synthesis and engineered to adhere to HER2 on tumor cells surface exhibit enhanced antitumor activitySemantic proximity Read ↗

Construction of humanized anti-HER2 single-chain variable fragments (husFvs) and achievement of potent tumor suppression with the reconstituted husFv-Fdt-tBid immunoapoptotin.Semantic proximity Read ↗

EphA2 Receptor Tyrosine Kinase as a Promising Target for Cancer TherapeuticsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.